Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;34(12):678-94.

Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths

Stephen V Faraone

Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths

Stephen V Faraone. P T. 2009 Dec.

Abstract

Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among agents are hindered by the absence of head-to-head clinical trials. By using meta-analysis, we sought to compare the efficacy of these medications for the symptoms of ADHD. We analyzed published literature on the pharmacotherapy of ADHD to describe the variability of drug-placebo effect sizes and conducted a literature search to identify double-blind, placebo-controlled studies of youths with ADHD that were published after 1979. Meta-analysis regression was used to assess the influence of the medication type on drug effects. We also assessed for publication bias.Thirty-two trials met our criteria and were included in this meta-analysis. These trials involved 16 drugs using 20 different outcome measures of ADHD behaviors. The effect sizes for immediate-release stimulants and long-acting stimulants were similar and were greater than the effect sizes for non-stimulants. There was no evidence of publication bias.Although nearly all of the ADHD medications had significant effects, we found substantial variability. When translated into the costs of treating large numbers of patients, these effect sizes have implications for formulary medication choices.

Keywords: ADHD; efficacy; medications.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Standardized mean differences and 95% confidence intervals (CIs) stratified by type of drug. The point indicates the effect size for each study. The horizontal line through each box gives the 95% CI. The diamonds give CIs for each type of drug. d-Amph = dextroamphetamine; ER = extended release; ES = effect size; GXR = guanfacine extended-release; IR = immediate release; LA = long-acting; LCI = lower 95% confidence interval; LDX = lisdexamfetamine dimesylate; MAS = mixed amphetamine salts; MPH = methylphenidate; MR = modified release; No. = number of observations; OROS = osmotic release oral system; UCI = upper 95% confidence interval; XR = extended release.
See this image and copyright information in PMC

References

    1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: Is it an American condition? World Psychiatr. 2003;2(2):104–113. - PMC - PubMed
    1. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005;9(2):384–391. - PubMed
    1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–723. - PMC - PubMed
    1. Biederman J, Faraone SV. Attention deficit hyperactivity disorder. Lancet. 2005;366(9481):237–248. - PubMed
    1. Chan E, Zhan C, Homer C.Health care use and costs for children with attention-deficit/hyperactivity disorder: National estimates from the Medical Expenditure Panel Survey Arch Pediatr Adolesc Med 20021565(5):504–511. - PubMed

LinkOut - more resources